EUCTR2006-001434-41-ES进行中（未招募）1 期
Estudio abierto, randomizado, multicéntrico y de grupos paralelos para demostrar el control de la anemia con RO0503821 administrando una vez cada 4 semanas inyecciones vía subcutánea en pacientes con enfermedad renal crónica que no están en diálisis - CORDATUS
F. Hoffmann-La Roche Ltd, Pharmaceuticals Division, PDR0 个研究点目标入组 300 人开始时间: 2010年3月11日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Written informed consent
- •2. Adult patients (=18 years old) with CKD stage 3 (CrCl/Glomerular filtration rate (GFR) 30-59 mL/min/1.73m2) or stage 4 (CrCl/GFR 15-29 mL/min/1.73m2) not
- •requiring dialysis. CrCl/GFR will be estimated at the first screening visit with the Cockcroft-Gault equation or the abbreviated MDRD equation, derived from the full MDRD equation.
- •3. Anemia defined as baseline Hb concentration < 10.5 g/dL determined from the mean of two screening values with at least one day between measurements
- •4. Adequate iron status defined as serum ferritin =100 ng/mL or TSAT =20% (or percentage of hypochromic RBCs <10%) determined from the mean of two screening values with at least one day between measurements
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Previous therapy with any ESA within 12 weeks prior to the first screening visit or during the screening period. If ESA treatment has been interrupted for at least 12 weeks, the patient may be enrolled in the study. Ongoing ESA treatment should not be discontinued to allow participation in the trial
- •2. Renal allograft in place
- •3. Immunosuppressive therapy (other than corticosteroids for a chronic condition, cyclosporine and monoclonal/polyclonal antibodies) in the 12 weeks before the first screening visit or during the screening period
- •4. Overt gastrointestinal bleeding within 8 weeks before screening or during the screening period
- •5. RBC transfusions within 8 weeks before screening or during the screening period
- •6. Hemoglobinopathies (e.g., homozygous sickle-cell disease, thalassemia of all types)
- •7. Hemolysis
- •8. Active malignant disease (except non-melanoma skin cancer). Patients with malignant disease who have been disease-free for at least the 5 previous years are eligible
- •9. Acute infection
- •10. Vitamin B12 deficiency
- •11. Folic acid deficiency
- •12. Poorly controlled hypertension (sitting SBP =160 mmHg or DBP =100 mmHg – average of two values with at least one day between measurements)
- •13. Epileptic seizure in the 6 months before screening
- •14. Pure red cell aplasia (PRCA) or history of PRCA
- •15. Planned elective surgery during the study period (patients who undergo vascular access surgery, cataract surgery or laser photocoagulation are eligible)
- •16. Life expectancy less than 12 months
- •17. Pregnancy or breast-feeding
- •18. Women of childbearing potential without effective contraception
- •19. Administration of another investigational drug within 4 weeks before screening or planned during the study period
- •20. Known hypersensitivity to any constituents of the study or reference drug formulations
- •21. Previous treatment with RO0503821
研究者
相似试验
进行中（未招募）
1 期
Estudio multicéntrico, abierto, randomizado, controlado, dos grupos, para evaluar el cumplimiento de la toma diaria en mujeres usuarias de contracepción oral con SHT00186D/BAY 86-5300 (0.02 mg de etinilestradiol como clatrato de betadex, y 3 mg de Drospirenona) en un régimen extendido y flexible, con el apoyo de un dispensador (CADDY) con función de recordatorio, durante 12 meses. (A multicenter, open-label, randomized, controlled, two-arm study to assess compliance with daily tablet intake of women on treatment with the oral contraceptive SH T00186D/BAY 86-5300 (0.02 mg ethinyl estradiol as betadex clathrate and 3 mg drospirenone) in a flexible extended regimen supported by a dispenser (CADDY) with a reminder function over 12 months) - EU-Compliance by buzzer study of YAZ Flex in the CADDYEUCTR2010-019902-17-ESBayer HealthCare AG
进行中（未招募）
不适用
Estudio multicéntrico, abierto, randomizado, de doce meses de duración, sobre la seguridad, tolerabilidad y eficacia de Certican®, administrado junto a un antagonista del receptor IL-2, corticoesteroides y dos niveles de exposición diferentes de tacrolimus, en pacientes con trasplante renal de novoTransplante renal de novode novo kidney transplantationEUCTR2005-001714-41-ESovartis Farmacéutica, S.A.230
进行中（未招募）
1 期
Estudio multicentrico, randomizado, abierto, para evaluar el inhibidor de la poli (ADP-ribosa) polimerasa 1 (PARP-1), BSI-201, administrado una o dos veces por semana, en combinación con gemcitabina/carboplatino en pacientes con cáncer de mama avanzado o metastásico triple negativo (mTNBC)__________________________________________________Multicenter, randomized, open label study evaluating a poly(ADP-ribose) polymerase-1(PARP-1) inhibitor, SAR240550 (BSI-201), administered twice weekly or weekly, in combination with gemcitabine/carboplatin, in patients with metastatic Triple Negative Breast Cancer (mTNBC)EUCTR2009-016091-80-ESsanofi-aventis recherche & développement80
进行中（未招募）
不适用
Estudio multicéntrico, aleatorizado, abierto, de grupos paralelos y controlado con tratamiento activo para determinar la seguridad y la eficacia de la albiglutida administrada en combinación con insulina glargina en comparación con la combinación de insulina glargina e insulina lispro preprandial en sujetos con diabetes mellitus de tipo 2.A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes MellitusDiabetes melitus de tipo 2.Type 2 Diabetes MellitusMedDRA version: 12.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2009-015386-30-ESSmithKline Beecham Corporation (doing business as GlaxoSmithKline)500
进行中（未招募）
不适用
Estudio multicéntrico, aleatorizado, abierto y de grupos paralelos para determinar la eficacia y la seguridad a largo plazo de la albiglutida en comparación con la insulina en sujetos con diabetes mellitus de tipo 2A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Long-Term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes MellitusDiabetes mellitus de tipo 2Type 2 Diabetes MellitusMedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusEUCTR2008-007661-24-ESGlaxoSmithKline Research and Development Ltd.750